EGFR Gene Mutation, NSCLC
Conditions
Brief summary
To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.
Interventions
OTHERneo-antigen vaccine
anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient voluntarily joined this study and signed an informed consent form; 2. ≥ 18 years old, both male and female; 3. Pathologically confirmed IIIB-IV stage NSCLC, with at least one measurable lesion that has not undergone local treatment (according to RECIST v1.1, the length of the measurable lesion on spiral CT or MRI scans is ≥ 10 mm or the short diameter of the enlarged lymph node is ≥ 15 mm); 4. Metastatic advanced EGFR mutated lung cancer confirmed by histology or cytology, with EGFR-TKI monotherapy or EGFR-TKI combined anti angiogenic therapy failing; 5. Patients who have received first-line chemotherapy in the past can be included in the inclusion criteria; 6. ECOG score: 0-2; 7. Expected survival time ≥ 12 weeks; 8. The functions of important organs meet the following requirements:Absolute neutrophil count ≥ 1.5 × 109/L;Absolute lymphocyte count ≥ 0.8 × 109/L;Platelets ≥ 80 × 109/L;Hemoglobin ≥ 90g/L;Bilirubin ≤ 1.5 × ULN (within 7 days before the first medication);ALT and AST ≤ 1.5 × ULN (within 7 days before the first medication); Serum creatinine ≤ 1.5 × ULN; 9. Thyroid stimulating hormone (TSH) ≤ 1 × ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously, and if FT3 and FT4 levels are normal, they can be included in the group level); 10. For female patients of childbearing age, effective methods of contraception should be used during the trial period and within 3 months after the last administration of treatment medication; 11. Agree to provide blood samples and histological specimens.
Exclusion criteria
1. The patient has any active autoimmune disease or a history of autoimmune disease; 2. The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage\>10mg/day of prednisone or other therapeutic hormones) ; 3. The patient experienced severe allergic reactions to other monoclonal antibodies; 4. Suffering from hypertension and unable to achieve good control through antihypertensive medication treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg); 5. There are clinical symptoms or diseases of the heart that cannot be well controlled, such as:NYHA grade 2 or above heart failure;Unstable angina pectoris; Have experienced myocardial infarction within 1 year;Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention; QTc\>450ms (male); QTc\>470ms (female); 6. Abnormal coagulation function (INR\>2.0, PT\>16s), with bleeding tendency or undergoing thrombolysis or anticoagulation treatment, allowing prophylactic use of low-dose aspirin and low molecular weight heparin; 7. Received previous anti-tumor immunotherapy and anti-tumor vaccine treatment; 8. The patient has active infection, unexplained fever ≥ 38.5 ° C within 7 days before medication, or baseline white blood cell count\>15 × 109/L; Those who may have purulent or chronic infections, and the wound persists without healing; 9. Patients who have experienced bone metastasis have received palliative radiotherapy in areas greater than 5% of the bone marrow area within the 4 weeks prior to participating in this study; 10. The patient has previously received anti PD-1, anti PD-L1, and anti PD-L2 treatment; 11. Those who are known to be allergic to the components of recombinant humanized anti-PD-1 monoclonal antibody drugs and vaccines; 12. Pregnant or lactating women, or female patients with fertility who have not taken contraceptive measures; 13. Other malignant tumors (excluding basal cell or squamous cell carcinoma, superficial bladder cancer cancer, cervical carcinoma in situ or breast cancer) in the past 5 years; 14. Patients who participate in other clinical trials at the same time; 15. HIV positive; HCV positive; Uncontrolled active hepatitis B; 16. Those who have received live vaccination within 4 weeks before the start of treatment; 17. Patients with a history of asymptomatic brain metastasis who meet all the following conditions can be selected:During screening, brain imaging showed no evidence of immediate progression.There is currently no need to use glucocorticoids to treat brain metastases, and stable doses of anticonvulsants are allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | three years | Exploration of the efficacy of anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC with previous EGFR-TKI treatment failure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | three years | Observe and evaluate the progression free survival (PFS), overal survival(OS) of advanced NSCLC patients who have failed previous EGFR-TKI treatment with anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy; |
| OS | three years | Observe and evaluate the overal survival(OS) of advanced NSCLC patients who have failed previous EGFR-TKI treatment with anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy; |
Countries
China
Contacts
Primary ContactBaorui Liu, MD,PhD
Backup ContactLifeng Wang, MD,PhD
Outcome results
None listed